Clinical trials: Methylphenidate, completed
Attention Deficit Hyperactivity Disorder
ERP Based Single-dose Predictions of Stimulants
The purpose of this study was to see if the clinical outcome of stimulant medication (methylphenidate) in pediatric Attention Deficit Hyperactivity Disorder can be predicted on the bases of changes in Event Related Potentials…
- Trial name
- NCT02695355
- Testing
- Methylphenidate (MPH)
- Where
- Norway
- Volunteers
- 87 people
- Sponsor
- Ostfold Hospital Trust
Attention Deficit/Hyperactivity Disorder
Cost-effectiveness of the Treatment of Attention Deficit/Hyperactivity Disorder With Methylphenidate Immediate-release in Brazil
The first objective is to measure the QALYs (Quality Adjusted Life Years) of Brazilian children and adolescents, submitted to methylphenidate immediate-release treatment for Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT01705613
- Where
- Brazil
- Volunteers
- 120 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Autism, Attention Deficit Disorder With Hyperactivity
Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children
This study examined the cognitive and behavioral differences in children who have an autism spectrum disorder (ASD) with or without additional symptoms of ADHD.
- Trial name
- NCT00178503
- Testing
- Methylphenidate-extended release, Methylphenidate-immediate release
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Attention Deficit-Hyperactivity Disorder
Real World Evidence of the Efficacy and Safety of FOQUEST
This study is a four-month, phase IV, open-label study of ADHD symptomatology and functional outcomes in pediatric (6 to 17 years old) and adult (≥18 years or older) patients with ADHD treated with FOQUEST or VYVANSE.
- Trial name
- reFOQus (NCT04152629)
- Testing
- Methylphenidate Hydrochloride, Lisdexamfetamine Dimesylate
- Where
- 12 sites in Canada
- Volunteers
- 257 people
- Sponsor
- Purdue Pharma, Canada
Healthy Volunteers
Methylphenidate and Cognitive Training in Elderly
Currently, there is no available drug to treat the symptoms of neurodegenerative and vascular cognitive disorders that affect millions of people worldwide.
- Trial name
- PACTE-1 (NCT03280251)
- Testing
- Methylphenidate, CogniPlus software, Pseudo cognitive training
- Where
- France
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Healthy
Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions
The objective of this randomized, single-dose, two-way evaluation is to compare the bioequivalence of a test dexmethylphenidate hydrochloride formulation to an equivalent oral dose of the commercially available dexmethylphenidate…
- Trial name
- NCT00829673
- Testing
- Dexmethylphenidate Hydrochloride
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Attention Deficit Disorder With Hyperactivity
Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder
This study will evaluate the effectiveness of a single drug versus a combination of drugs in treating attention deficit hyperactivity disorder in children.
- Trial name
- Project1 (NCT00429273)
- Testing
- Guanfacine, Methylphenidate (MPH)
- Where
- United States
- Volunteers
- 212 people
- Sponsor
- University of California, Los Angeles
Attention Deficit Hyperactivity Disorder
A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder
The primary purpose of your child's participation in this study is to determine whether LY2216684 can help pediatric patients with attention-deficit/hyperactivity disorder (ADHD); and assess the safety of LY2216684 and any side…
- Trial name
- NCT00922636
- Testing
- LY2216684, Methylphenidate
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
Neurofibromatosis Type 1
NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with an estimated prevalence of 1/2190 to 1/6711. Attention deficit hyperactivity disorder (ADHD) has been reported to be common in NF1.
- Trial name
- NCT00169611
- Testing
- methylphenidate
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Hospices Civils de Lyon
ADHD, Smoking
Family Risk Analysis of Substance Use in Attention Deficit Hyperactivity Disorder (ADHD) Youth Treated With Concerta
The researchers will study 100 families over three years, each with a child (proband) between the ages of 12-17, with the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of ADHD.
- Trial name
- NCT00181792
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Cocaine-Related Disorders
Cocaine-Methylphendidate Interaction Study - 4
The purpose of this study is to attempt to identify possible dangerous interactions between cocaine and methylphenidate (MPD). Additional objectives are to determine: a) if MPD reduces the craving and high for cocaine; b) if…
- Trial name
- NCT00015067
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Social Cognition
Effects of MDMA and Methylphenidate on Social Cognition
The purpose of this study is to assess and compare the effects of a single dose of 3,4-methylenedioxymethamphetamine (MDMA)and methylphenidate (MPH) on emotional and social cognition in healthy subjects.
- Trial name
- NCT01616407
- Testing
- 3,4-Methylenedioxymethamphetamine, Methylphenidate
- Where
- Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
ADHD
Evaluation of Use of Brain Activity Monitoring Dynamics in ADHD
This study evaluates the ability to support diagnosis and monitor of the dynamics in ADD/ADHD subjects with an easy to use EEG Device.
- Trial name
- NCT02625805
- Testing
- EEG monitoring (MindWave by NeuroSky), EEG monitoring (EPOC by Emotiv), Methylphenidate
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Brainmarc Ltd.
ADHD
Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta
This study will consist of a six-week open-label treatment period with an extended duration methylphenidate (OROS MPH) followed by subsequent monthly visits for 24 months in a large sample of youths aged 12-17 who meet Diagnostic…
- Trial name
- NCT00181714
- Testing
- methylphenidate HCl (Concerta)
- Where
- United States
- Volunteers
- 203 people
- Sponsor
- Massachusetts General Hospital
Brain Injury
Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)
Traumatic brain injury (TBI) is a significant public health problem, with 1.5-2.0 million Americans injured each year. Cognitive deficits, particularly in the domains of memory and attention are frequently the source of lingering…
- Trial name
- NCT00453921
- Testing
- Methylphenidate, Memory and Attention Training
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
ADHD
A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
This study will look at how centanafadine works when taken together with stimulant medicines in healthy adults, and whether combining them affects how the body responds.
- Trial name
- NCT07314333
- Testing
- Centanafadine, Methylphenidate, Lisdexamfetamine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
ADHD
The Effects of ADHD Medication (TEAM) Study
This study evaluates the effects of receiving and then discontinuing methylphenidate (MPH) in children with ADHD. After receiving MPH for 8 weeks, participants will be randomized to either discontinue MPH (and receive placebo) OR…
- Trial name
- TEAM (NCT02293655)
- Testing
- OROS-Methylphenidate (MPH)
- Where
- 2 sites in United States
- Volunteers
- 204 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Healthy
Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions
The objective of this randomized, single-dose, two-way evaluation is to compare the bioequivalence of a test dexmethylphenidate hydrochloride formulation to an equivalent oral dose of the commercially available dexmethylphenidate…
- Trial name
- NCT00829712
- Testing
- Dexmethylphenidate Hydrochloride
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
ADHD, Opioid-Related Disorders
Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1
The purpose of this study is to treat Adult Attention Deficit Hyperactivity Disorder (ADHD) in methadone patients.
- Conditions
- ADHD, Opioid-Related Disorders, Cocaine Dependence
- Trial name
- NCT00061087
- Testing
- Methylphenidate, Bupropion
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- New York State Psychiatric Institute
Attention Deficit Disorder With Hyperactivity
The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate whether familial relationships and psychological status of participants or caregivers as well as Attention Deficit Hyperactivity Disorder (ADHD) symptoms of participants can be improved by…
- Trial name
- NCT00758160
- Testing
- OROS Methylphenidate
- Volunteers
- 296 people
- Sponsor
- Johnson & Johnson Taiwan Ltd